Clinical trial
A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the…
NCT00002318 · Sequus Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00002318 |
|---|---|
| Title | A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma |
| Official title | Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma |
| Lead sponsor | Sequus Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sarcoma, Kaposi, HIV Infections |
| Intervention type | Drug |
| Interventions | Doxorubicin hydrochloride (liposomal), Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride |
| Enrollment | 225 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: